Merck
During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its manufacturing.
Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda
The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.
Merck Buys Exclusive Rights to Develop Hengrui Pharma's Lp(a) Inhibitor Outside of China
Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.
Actinium Launches Clinical Program to Test Actimab-A With PD-1 Inhibitors in Solid Tumors
The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.
Merck's Welireg Approved in Europe for Von Hippel-Lindau-Associated Cancers
The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.